Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13618223 | 0.79 | ALDH1A1 (0.54) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL18908668 | 0.77 | SMN1; SMN2 (0.59) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL18660789 | 0.74 | POLB (0.37) | TP53ALDH1A1TSHRKDM4E | |
| SCHEMBL22338220 | 0.74 | TSHR (0.45) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL25083177 | 0.74 | TSHR (0.45) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL20340484 | 0.73 | SMN1; SMN2 (0.66) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL18199495 | 0.73 | SMN1; SMN2 (0.66) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL18685685 | 0.73 | TSHR (0.49) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL607171 | 0.71 | SMN1; SMN2 (0.53) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL1577892 | 0.71 | SMN1; SMN2 (0.53) | SMN1; SMN2TP53HPGDALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20230399356-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-14 | — | — | US | disclosed |
| US-11725024-B2 | Antibody drug conjugates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-15 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| US-20220168330-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| US-10980825-B2 | Cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-15 | — | — | US | disclosed |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | SMN1; SMN2 1815/4885TP53 824/4885HPGD 1805/4885 |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | SMN1; SMN2 1815/4885TP53 824/4885HPGD 1805/4885 |
| US-20220168330-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | SMN1; SMN2 3380/4885TP53 1115/4885HPGD 3918/4885 |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | SMN1; SMN2 1484/4885TP53 764/4885HPGD 1108/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | SMN1; SMN2 3733/4885TP53 3540/4885HPGD 1842/4885 |
| US-10980825-B2 | Cyclic dinucleotide | STING1, CGAS, MAVS | SMN1; SMN2 1484/4885TP53 764/4885HPGD 1108/4885 |
| US-20230399356-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | SMN1; SMN2 3380/4885TP53 1115/4885HPGD 3918/4885 |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | SMN1; SMN2 1484/4885TP53 764/4885HPGD 1108/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | SMN1; SMN2 1815/4885TP53 824/4885HPGD 1805/4885 |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | SMN1; SMN2 3558/4885TP53 1644/4885HPGD 3444/4885 |
| US-11725024-B2 | Antibody drug conjugates | STING1, CGAS, TBK1 | SMN1; SMN2 3380/4885TP53 1115/4885HPGD 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.